We are live on ! Find out more
FATE icon

Fate Therapeutics
FATE

167 hedge funds and large institutions have $904M invested in Fate Therapeutics in 2024 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 48 increasing their positions, 52 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

324% more call options, than puts

Call options by funds: $1.69M | Put options by funds: $399K

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

150% more capital invested

Capital invested by funds: $362M → $904M (+$542M)

32% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 31

25.92% more ownership

Funds ownership: 98.19% → 124.12% (+26%)

5% more funds holding

Funds holding: 159 → 167 (+8)

8% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 52

Holders
167
Holders Change
+8
Holders Change %
+5.03%
% of All Funds
2.41%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
41
Increased
48
Reduced
52
Closed
31
Calls
$1.69M
Puts
$399K
Net Calls
+$1.29M
Net Calls Change
+$1.23M

Top Buyers

1
BC
Boxer Capital
California
+$47.8M
2
State Street
State Street
Massachusetts
+$38.2M
3
DTC
Deep Track Capital
Connecticut
+$34.5M
4
SCM
Suvretta Capital Management
New York
+$15.9M
5
Holocene Advisors
Holocene Advisors
New York
+$15.6M

Top Sellers

1
BlackRock
BlackRock
New York
-$13.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$11.8M
3
MAM
Monaco Asset Management
Monaco
-$11.6M
4
Two Sigma Investments
Two Sigma Investments
New York
-$7.96M
5
CC
Casdin Capital
New York
-$7.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$10.6M -$2.72M -439,200 -23%
O
27
OrbiMed
New York
$9.95M +$5.12M +827,272 +157%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$7.8M +$4.6M +742,405 +231%
Federated Hermes
29
Federated Hermes
Pennsylvania
$7.39M -$5.21M -842,494 -46%
Invesco
30
Invesco
Georgia
$7.09M +$5.17M +835,977 +646%
Charles Schwab
31
Charles Schwab
California
$7.02M -$165K -26,688 -3%
SCM
32
Superstring Capital Management
New York
$6.76M +$450K +72,653 +9%
SSA
33
Schonfeld Strategic Advisors
New York
$6.51M +$2.41M +389,468 +78%
SCM
34
Soleus Capital Management
Connecticut
$6.39M +$5.39M +870,000 New
VPC
35
Vestal Point Capital
New York
$5.87M -$3.03M -490,000 -38%
Rafferty Asset Management
36
Rafferty Asset Management
New York
$5.36M +$4.52M +729,657 New
Northern Trust
37
Northern Trust
Illinois
$5.26M +$46.2K +7,463 +1%
TCM
38
Tang Capital Management
California
$5.14M – – –
Citigroup
39
Citigroup
New York
$4.57M -$1.37M -220,904 -26%
OCA
40
Octagon Capital Advisors
New York
$3.82M +$3.22M +520,800 New
GGH
41
GCM Grosvenor Holdings
Illinois
$3.64M – – –
Hudson Bay Capital Management
42
Hudson Bay Capital Management
Connecticut
$3.38M +$2.85M +460,000 New
UBS Group
43
UBS Group
Switzerland
$3.26M +$1.66M +267,745 +152%
Prudential Financial
44
Prudential Financial
New Jersey
$2.81M -$1.09M -176,810 -32%
Voloridge Investment Management
45
Voloridge Investment Management
Florida
$2.78M +$2.34M +378,608 New
AG
46
Artal Group
Luxembourg
$2.64M +$2.23M +360,311 New
Marshall Wace
47
Marshall Wace
United Kingdom
$2.54M +$2.14M +345,437 New
Barclays
48
Barclays
United Kingdom
$2.38M -$217K -35,132 -10%
MAM
49
Monaco Asset Management
Monaco
$2.33M -$11.6M -1,866,423 -85%
Bank of New York Mellon
50
Bank of New York Mellon
New York
$2.22M -$124K -19,959 -6%
1
2
3 4 5

FATE Hedge Fund Activity: Q1 2024 in Review

167 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2024, worth a combined $904M — up 150% from $362M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new FATE positions and 31 closed out — a net gain of 10 holders — while 48 added to existing stakes and 52 trimmed.

The largest buyer was Boxer Capital, adding an estimated $47.8M. The largest seller was BlackRock, cutting an estimated $13.1M.

  • 167 institutional investors held Fate Therapeutics (FATE) as of Q1 2024, up from 159 in Q4 2023.
  • Funds reported $904M of Fate Therapeutics stock for Q1 2024, up 150% quarter-over-quarter.
  • 41 funds opened new Fate Therapeutics positions in Q1 2024 and 31 closed out, a net change of +10 holders.
  • The largest Fate Therapeutics buyer in Q1 2024 was Boxer Capital, an estimated $47.8M added.
  • The largest Fate Therapeutics seller in Q1 2024 was BlackRock, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2024.